Serum miRNA125a-5p, miR-125b-5p, and miR-433-5p as biomarkers to differentiate between posterior circulation stroke and peripheral vertigo

Naruchorn Kijpaisalratana1,2,3, Pattaraporn Nimsamer4, Ariya Khamwut5, Sunchai Payungporn5, Trairak Pisitkun4, Aurauma Chutinet1,6, Nattawan Utoomprurkporn7,8, Stephen J. Kerr9,10,11, Pakkawan Vongvasinkul6 and Nijasri C. Suwanwela1,3,6*

Abstract

Background: Acute vertigo is a common presentation of inner ear disease. However, it can also be caused by more serious conditions, especially posterior circulation stroke. Differentiating between these two conditions by clinical presentations and imaging studies during the acute phase can be challenging. This study aimed to identify serum microRNA (miRNA) candidates that could differentiate between posterior circulation stroke and peripheral vertigo, among patients presenting with acute vertigo.

Methods: Serum levels of six miRNAs including miR-125a-5p, miR-125b-5p, miR-143-3p, miR-342-3p, miR-376a-3p, and miR-433-5p were evaluated. Using quantitative reverse-transcription polymerase chain reaction (RT-qPCR), the serum miRNAs were assessed in the acute phase and at a 90 day follow-up visit.

Results: A total of 58 patients with posterior circulation stroke (n = 23) and peripheral vertigo (n = 35) were included in the study. Serum miR-125a-5p (P = 0.001), miR-125b-5p (P < 0.001), miR-143-3p (P = 0.014) and miR-433-5p (P = 0.0056) were present at significantly higher levels in the acute phase, in the patients with posterior circulation infarction. Based on the area under the receiver operating characteristic curve (AUROC) only miR-125a-5p (0.75), miR-125b-5p(0.77), and miR-433-5p (0.71) had an acceptable discriminative ability to differentiate between the central and peripheral vertigo. A combination of miRNAs revealed no significant improvement of AUROC when compared to single miRNAs.

Conclusion: This study demonstrated the potential of serum miR-125a-5p, miR-125b-5p, and miR-433-5p as biomarkers to assist in the diagnosis of posterior circulation infarction among patients presenting with acute vertigo.

Keywords: Acute vertigo, Stroke biomarker, microRNA, Posterior circulation stroke, Central vertigo, Peripheral vertigo

* Correspondence: nijasris@yahoo.com

1Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok 10330, Thailand
2Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
3Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Acute vertigo is a common presentation of inner ear disease. However, it can also be caused by more serious conditions, particularly posterior circulation stroke. Differentiating between these two conditions during the acute phase of vertigo on the basis of clinical presentations and imaging studies can be challenging. Although a combination of bedside physical examinations consisting of head impulse test, nystagmus, and test of skew (HINTS) has both high sensitivity and specificity for differentiating posterior circulation stroke from peripheral vertigo [1], the test is not applicable in most patients especially after vestibular symptoms have resolved [2]. Computed tomography (CT) is not sensitive for diagnosing posterior circulation stroke [3]. Although magnetic resonance imaging (MRI) has higher sensitivity, initial MRI done within the first 48 h can miss the infarctions in 12% of patients [1].

MicroRNA (miRNA) is a small non-coding ribonucleic acid containing 20–24 nucleotides. MiRNA regulates protein synthesis which is a biological stage and organ-specific [4]. It is stable in various body fluids, a factor contributing to its potential as a biomarker [5, 6]. MiRNAs have been demonstrated to have prognostic, diagnostic, and therapeutic biomarker properties among stroke patients [7].

Aims
Due to the diagnostic challenge in patients presenting with acute vertigo, this study aimed to determine the potential of miRNA as a biomarker to differentiate between central vertigo due to posterior circulation infarction and peripheral vertigo. Serum levels of 6 miRNAs including 3 previously reported miRNAs: miR-125a-5p, miR-125b-5p, miR-143-3p [8] and 3 miRNAs identified in a pilot study by NanoString nCounter Analysis (Supplementary material): miR-342-3p, miR-376a-3p, and 433-5p were evaluated in patients presenting with acute vertigo.

Methods
Study design and study population
This is a single-center prospective cohort study conducted between June 2017–December 2019. The study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No. 131/60). Written informed consent was obtained from every patient prior to the enrollment. Patients aged ≥ 45 years old with acute vertigo who presented to the emergency department of King Chulalongkorn Memorial Hospital within 72 h after symptom onset were consecutively screened for eligibility. Exclusion criteria were patients with altered consciousness, body temperature > 100.4 °F, white blood cell count > 15,000 cell/μL, serum creatinine > 2 mg/dl, liver enzymes > 3 fold of upper normal limit or cirrhosis, known history of active malignancy or autoimmune disease, and concurrent intracranial pathology other than acute ischemic stroke.

Diagnosis of posterior circulation stroke
The final diagnosis of central vertigo due to ischemic stroke was made by a neurologist and confirmed by the presence of restricted diffusion in the diffusion-weighted images on MRI. MRI studies were performed using a 3-Tesla scanner (Skyra, Siemens, Erlangen, Germany). Ischemic stroke severity was assessed according to the National Institute of Health Stroke Scale (NIHSS) by a trained neurologist. The cerebral infarction volume was quantified by the diffusion weighted images on 3-Tesla MRI, using Olea Sphere™ Version 3.0 software (Olea Medical®, La Ciotat, France).

Diagnosis of peripheral vertigo
Peripheral vertigo was diagnosed by an otolaryngologist according to the diagnostic criteria of benign paroxysmal positional vertigo (BPPV) [9] and Meniere’s disease [10]. The diagnosis of vestibular neuritis was made by agreement between both neurologist and otolaryngologist, and confirmed by absence of any evidence of cerebral infarction on MRI. MRI was performed in all patients whose clinical not compatible with the diagnostic criteria of BPPV and Meniere’s disease. In case of negative MRI study, they were classified as “MRI-negative other peripheral vertigo”.

Specimen collection and miRNA isolation
Blood was collected within 72 h after onset of acute vertigo upon arrival and at a follow-up visit on day 90. Venous blood was collected in tubes containing clot activator. After 30 min of coagulation, serum supernatant was separated by centrifugation at 1000 g, 4 °C, for 15 min, followed by an additional serum centrifugation at 2500 g, 4 °C, for 15 min to remove residual debris. Serum was frozen and stored at −80 °C until used. MiRNAs were isolated from 200 μl of the serum using Geneaid® miRNA isolation kit (Geneaid Biotech Ltd., New Taipei City, Taiwan) according to the manufacturer’s protocol.

RT-qPCR
The miRNA candidates were quantified by RT-qPCR. First, the miRNA was polyuridylated by poly(U) polymerase (New England BioLabs®, Ipswich, MA, USA). Then, the cDNA molecules were reverse transcribed by the universal poly(A) stem-loop RT primers. Finally, the miRNA quantification was performed by real-time PCR using the SYBR® Green fluorescence (New England BioLabs®, Ipswich, MA, USA) [11]. Absolute quantification of the target miRNAs in serum sample was performed by the standard curve method. A standard curve was generated by serial dilution of a known concentration of the target miRNAs. Quantification of miRNA level was performed by laboratory staff blinded to clinical presentation and neuroimaging findings.
Statistical analysis
Visual inspection of graphs and the Kolmogorov-Smirnov test was used to determine whether data was normally distributed. Continuous variables were presented as mean ± standard deviation (SD) or median with interquartile range (IQR), as appropriate. Unpaired-t tests or Mann-Whitney U tests were used to formally compare study group characteristics between central and peripheral vertigo groups, for data with continuous normal and non-normal distributions, respectively. Categorical variables were presented as frequencies and percentages. Mann-Whitney U tests were used to compare miRNA levels between groups at each timepoint. Paired within group comparisons of non-normal data were made using a Wilcoxon signed rank test. Spearman’s rho was used to assess correlations between miRNA levels and ischemic stroke severity by NIHSS and infarct volume. Receiver operating characteristic (ROC) curves were generated to demonstrate the discriminative ability of the biomarkers to distinguish between central and peripheral vertigo groups. Binary logistic regression was performed to assess the association between miRNAs and stroke, after adjusting for potential confounders, that were imbalanced between study group. We used Youden’s index to determine cutoffs defining the maximum potential effectiveness of the miRNAs. Missing data at the follow-up period on day 90 were excluded from analysis. Statistical analysis was performed by SPSS 22.0 for Mac software package (SPSS, Inc., Chicago, IL, USA) and STATA 15 for windows (StataCorp, LLC., College Station, TX, USA). Graphs demonstrating biomarker levels were generated by Prism 8 for OS X (GraphPad Software, Inc., San Diego, CA, USA).

Results
Patient characteristics
A total of 58 patients, 23 with central vertigo due to posterior circulation stroke and 35 with peripheral vertigo were studied. Patients with posterior circulation stroke included cerebellar infarction (52%), brainstem infarction (26%), and

Table 1 Baseline characteristics, laboratory parameters, and medication in acute vertigo patients

|                                | Central Vertigo (n = 23) | Peripheral Vertigo (n = 35) | P value |
|--------------------------------|--------------------------|-----------------------------|---------|
| Age, years, mean (SD)          | 64.52 (11.80)            | 63.69 (9.42)                | 0.766   |
| Female, % (n)                  | 21.7% (5)                | 82.9% (29)                  | 0.001*  |
| Body mass index, kg/m², mean (SD) | 24.89 (3.96)            | 24.56 (4.62)                | 0.59    |
| Onset to blood collection (hrs), mean (SD) | 37.59 (16.94)       | 21.35 (17.91)               | 0.001*  |
| Stroke risk factors, % (n)     |                          |                             |         |
| - Hypertension                 | 65.2% (15)               | 51.4% (18)                  | 0.30    |
| - Diabetes mellitus            | 52.2% (12)               | 17.1% (6)                   | 0.005*  |
| - Dyslipidemia                 | 56.5% (13)               | 48.6% (17)                  | 0.55    |
| - History of stroke            | 13.0% (3)                | 28.6% (10)                  | 0.17    |
| - History of myocardial infarction | 21.7% (5)               | 2.9% (1)                    | 0.02*   |
| - Smoking                      | 26.1% (6)                | 0                           | 0.001*  |
| Previous history of vertigo, % (n) | 13% (3)                       | 31.4% (11)                  | 0.11    |
| Systolic BP, mmHg, med (IQR)   | 161 (146–170)            | 149 (139–168)               | 0.10    |
| Diastolic BP, mmHg, med (IQR)  | 90 (75–100)              | 80 (68–90)                  | 0.14    |
| Pulse rate, bpm, med (IQR)     | 80 (60–85)               | 76 (70–82)                  | 0.87    |
| Laboratory parameters          |                          |                             |         |
| - Hemoglobin, g/dL, med (IQR)  | 13.7 (13.1–15.4)         | 13.0 (12.5–13.4)            | 0.009*  |
| - WBC count, *10³/μL, mean (SD) | 9.91 (2.95)              | 8.29 (2.21)                 | 0.03*   |
| - Platelets, *10³/μL, mean (SD) | 227.61 (66.43)         | 266.24 (81.14)              | 0.07    |
| - Creatinine, mg/dL, med (IQR) | 0.84 (0.71–0.98)         | 0.67 (0.61–0.82)            | 0.04*   |
| - Fasting blood sugar, mg/dL, med (IQR) | 130.0 (103–154)       | 100.0 (80–113.5)            | 0.008*  |
| - HbA1C, %, med (IQR)          | 6.3 (5.6–7.2)            | 5.6 (5.28–6.2)              | 0.02*   |
| Medication, n(%)               |                          |                             |         |
| - Antiplatelets                | 17.4% (4)                | 37.1% (13)                  | 0.11    |
| - Anticoagulant                | 0% (0)                   | 2.9% (1)                    | 0.31    |

WBC white blood cell, LDL low density lipoprotein, HDL high density lipoprotein, SGOT serum glutamic-oxaloacetic transaminase, SGPT serum glutamic pyruvic transaminase, ALP alkaline phosphatase, ACEI angiotensin-converting enzyme inhibitor, ARBs angiotensin II receptor blockers *P < 0.05
miR-125a-5p 568.7 (338.2–*

miRNA level [median (IQR)] Central Vertigo (n = 23) Peripheral Vertigo (n = 35) P value

miR-125a-5p 568.7 (338.2–924.5) 244.5 (1608–495.1) 0.001*
mir-125b-5p 125.0 (98.0–199.8) 48.6 (22.6–103.7) < 0.001*
mir-143-3p 321.6 (188.7–407.2) 172.5 (102.2–242.2) 0.014*
mir-342-3p 44.8 (16.3–118.7) 37.76 (14.57–136.4) 0.81
mir-376a-3p 134.3 (78.0–209.5) 87.93 (56.6–167.6) 0.056
mir-376b-3p 92.13 (49.0–183.2) 53.45 (35.3–102.3) 0.006*

HINTS head impulse test, nystagmus, test of skew deviation
*P < 0.05

both cerebellar and brainstem infarction (22%). In peripheral vertigo group, there were patients with BPPV (49%), Meniere’s Disease (11%), vestibular neuritis (11%), and MRI-negative other peripheral vertigo (29%). Most of the baseline characteristics among 2 groups were comparable with the exception of longer onset to blood collection time, higher number of females, diabetics, patients with previous myocardial infarction, and current smokers among those with posterior circulation stroke. (Table 1). No recruited patients received low/high molecular weight heparin prior to blood sampling for miRNA analysis.

Clinical presentations

The signs and symptoms of spinning, sense of imbalance, nausea and vomiting, oscillopsia, and nystagmus in both groups were indistinguishable. Physical signs including skew deviation, diplopia, and limb ataxia were found exclusively in the patients with central vertigo. A positive HINTS test was found only amongst 4 (11.4%) of peripheral vertigo patients. However, this was not statistically significant (Table 2).

Serum miRNAs expression level

During the acute phase, 4 out of 6 selected miRNAs including miR-125a-5p, miR-125b-5p, miR-143-3p, and miR-433-5p were present at significantly higher level among patients with central vertigo due to posterior circulation infarction. (Table 3, Fig. 1).

We assessed the correlation between distinct miRNA levels using Spearman’s rank correlation. All showed significant correlations (P < 0.001) with Spearman’s rho ranging from 0.4403–0.8472, with the exception of mirR342-3p which only showed a significant correlation with mirR376a-3p. (Supplementary Table 1).

In the temporal expression profile study, serum miRNA levels were measured in the acute phase and on day 90. One patient in the central vertigo group and 6 patients in the peripheral vertigo group were lost to follow-up on day 90. The levels of miR-125a-5p (median (IQR): central: 569.9 (337.2–927.8) copies/μL vs. peripheral: 244.5 (156.0–496.6) copies/μL, P = 0.004), mirR125b-5p (central: 122.2 (88.5–195.3) copies/μL vs. peripheral: 56.0 (22.6–113.9) copies/μL, P = 0.003), mirR143-3p (central: 326.4 (210.1–418.1) copies/μL vs. peripheral: 165.4 (100.3–238.0) copies/μL, P = 0.007), mirR376a-3p (central: 136.8 (80.1–214.5) copies/μL vs. peripheral: 77.9 (50.0–160.8) copies/μL, P = 0.029), and mirR433-5p (central: 88.1 (48.9–172.3) copies/μL vs. peripheral: 44.0 (33.0–101.1) copies/μL, P = 0.011) were significantly higher during the acute phase in patients with central vertigo. The level of mirR125a-5p (acute: 569.9 (337.2–927.8) copies/μL vs. day 90: 242.4 (120.0–326.9) copies/μL, P = 0.008); mirR125b-5p (acute: 122.2 (88.5–195.3) copies/μL vs. day 90: 38.2 (14.0–106.4) copies/μL, P = 0.003); mirR143-3p (acute: 326.4 (210.1–418.1) copies/μL vs. day 90: 141.9 (81.0–268.3) copies/μL, P = 0.03), and mirR376a-3p (acute: 136.8 (80.1–214.5) copies/μL vs. day 90: 71.7 (30.8–123.3) copies/μL, P = 0.01) were significantly decreased by day 90 in stroke patients. In the peripheral vertigo patients, there were

Table 2 Clinical presentations of acute vertigo

| Clinical presentations | Central Vertigo (n = 23) | Peripheral Vertigo (n = 35) | P value |
|------------------------|-------------------------|-----------------------------|---------|
| Sense of spinning       | 65.2% (15)              | 82.9% (29)                  | 0.13    |
| Sense of imbalance      | 95.7% (22)              | 88.6% (31)                  | 0.35    |
| Nausea/vomiting         | 60.9% (14)              | 77.1% (27)                  | 0.18    |
| Positive HINTS          | 0% (0)                  | 11.4% (4)                   | 0.09    |
| Nystagmus               | 47.8% (11)              | 54.4% (19)                  | 0.63    |
| Bilateral direction     | 17.4% (4)               | 0% (0)                      |         |
| changing                |                         |                             |         |
| Vertical                | 4.3% (1)                | 0% (0)                      |         |
| Torsional               | 0% (0)                  | 0% (0)                      |         |
| Unidirectional          | 13.0% (3)               | 17.1% (6)                   |         |
| horizontal              |                         |                             |         |
| Multidirectional        | 13.0% (3)               | 0% (0)                      |         |
| Diagnostic maneuver     | 0% (0)                  | 37.0% (13)                  |         |
| Skew deviation          | 13.0% (3)               | 0% (0)                      | 0.03*   |
| Diplopia                | 30.4% (7)               | 0% (0)                      | 0.001*  |
| Oscillopsia             | 8.7% (2)                | 8.6% (3)                    | 0.99    |
| Limb ataxia             | 18 (78.3%)              | 0% (0)                      | < 0.001*|

Table 3 Biomarker level during acute phase in patients with central and peripheral vertigo

| miRNA level [median (IQR)] | Central Vertigo (n = 23) | Peripheral Vertigo (n = 35) | P value |
|---------------------------|-------------------------|-----------------------------|---------|
| miR-125a-5p               | 568.7 (338.2–924.5)     | 244.5 (1608–495.1)          | 0.001*  |
| miR-125b-5p               | 125.0 (98.0–199.8)      | 48.6 (22.6–103.7)           | < 0.001*|
| miR-143-3p                | 321.6 (188.7–407.2)     | 172.5 (102.2–242.2)         | 0.014*  |
| miR-342-3p                | 44.8 (16.3–118.7)       | 37.76 (14.57–136.4)         | 0.81    |
| miR-376a-3p               | 134.3 (78.0–209.5)      | 87.93 (56.6–167.6)          | 0.056   |
| miR-376b-3p               | 92.13 (49.0–183.2)      | 53.45 (35.3–102.3)          | 0.006*  |

*P < 0.05
no significant differences in the levels of all 6 miRNAs between the acute phase and day 90 (Fig. 2).

Binary logistic regression was performed to determine associations between serum miRNAs and diagnosis of posterior circulation stroke. In both univariate and multivariate analyses after adjusting for sex, onset to blood collection time, diabetes mellitus, history of myocardial infarction, and smoking, serum miR-125a-5p, miR-125b-5p, miR-143-3p, and miR-433-5p were associated with the diagnosis of stroke (Supplementary Table 2).

Relationship of miRNAs level with ischemic stroke severity

The median (IQR) stroke severity determined by NIHSS in the patients with acute vertigo due to posterior circulation infarction was 3 (2-6). There was no correlation between the NIHSS and the serum level of miRNAs (Supplementary Table 3). The median (IQR) volume of infarction was 4.51 (0.66–16.26) ml. Serum miR-125a-5p and miR-376a-3p demonstrated weak positive correlation with the cerebral infarction volume which remained significant after correction for multiple testing (Supplementary Table 4). In addition to stroke severity, there was no correlation between the miRNA level and the onset to blood collection time among patients with posterior circulation infarction (Supplementary Table 5).

Diagnostic ability of serum miRNA in acute vertigo

The areas under the ROC curve (95%CI) of the six serum miRNAs are demonstrated in Table 4. Based on the AUROC and 95% CI, only miR-125a-5p, miR-125b-5p, and miR-433-5p had an acceptable ability to differentiate between the central and peripheral vertigo. All possible combination of these 3 miRNAs including miR-125a-5p, miR-125b-5p, and miR-433-5p were examined and revealed no statistically improvement of the discriminative ability (Supplementary Table 6 and Supplementary Figure 2). Optimal cut off levels determined by Youden’s index were: miR-125a-5p: 299 copies/μL (sensitivity: 87.0%; specificity:
57.1%); miR-125b-5p: 89 copies/μL (sensitivity: 78.3%; specificity: 74.3%); miR-433-5p: 46 copies/μL (sensitivity: 87%; specificity: 48.6%).

**Discussion**

Serum levels of miR-125a-5p, miR-125b-5p, miR-143-3p, and miR-433-5p were present at significantly higher levels among patients with central vertigo due to posterior circulation infarction in both the acute phase and temporal expression profile studies. However, based on AUROC analysis, only miR-125a-5p, miR-125b-5p, and miR-433-5p demonstrated potential as posterior circulation stroke biomarkers for diagnosis of acute vertigo. Serum levels of miR-125a-5p and miR-125b-5p significantly decreased by day 90 among patients with posterior circulation infarction. These findings suggest that the elevation of both miR-125a-5p and miR-125b-5p occurred in the acute phase of ischemic stroke, and emphasize the capability of these miRNAs as posterior circulation stroke biomarkers.

Interestingly, there were no significant differences in the expression level of serum miR-125a-5p, miR-125b-5p, and miR-433-5p between the patients with central and peripheral vertigo on day 90 and in the patients with peripheral vertigo between day 0 and day 90. This temporal expression pattern might be useful in elucidating the mechanism of

| miRNA Combination         | AUROC  | 95% CI          |
|---------------------------|--------|-----------------|
| miR-125a-5p               | 0.7516 | 0.6196–0.8835   |
| miR-125b-5p               | 0.7689 | 0.6418–0.8961   |
| miR-143-3p                | 0.6919 | 0.5523–0.8315   |
| miR-342-3p                | 0.5193 | 0.3674–0.6712   |
| miR-376a-3p               | 0.6497 | 0.5042–0.7952   |
| miR-433-5p                | 0.7143 | 0.5780–0.8506   |
| miR-125a-5p + miR-125b-5p | 0.7665 | 0.6382–0.8948   |
| miR-125a-5p + miR-433-5p  | 0.7503 | 0.6171–0.8835   |
| miR-125b-5p + miR-433-5p  | 0.7590 | 0.6282–0.8899   |
| miR-125a-5p + miR-125b-5p + miR-433-5p | 0.7627 | 0.6345–0.8910  |
miRNA involvement in the pathophysiology and pathogenesis of acute ischemic stroke. An elevation of serum miRNA in the acute phase of ischemic stroke is possibly due to the passive release from ischemia-vulnerable neurons [12] or by active secretion via extracellular vesicles [8, 13].

The sensitivity of serum miR-125a-5p, miR-125b-5p, and miR-433-5p to identify patients with posterior circulation stroke in our study was higher than that previously reported using CT scan as a diagnostic neuroimaging tool. Our study demonstrated low or no correlation between the level of serum miRNAs in ischemic stroke, and severity determined by both the NIHSS and infarction volume. Our findings are consistent with those previously reported by Tiedt et al. [8] which emphasized the potential of these biomarker candidates as adjuncts in the diagnosis of acute ischemic stroke regardless of stroke severity.

MiR-125a-5p and miR-125b-5p have previously shown associations with acute ischemic stroke from an RNA sequencing study [8]. An in vivo experiment demonstrated that miR-125a-5p regulates blood brain barrier function [14]. MiR-125b-5p has previously been shown to be a predictive biomarker candidate for ischemic stroke outcomes [15, 16]. MiR-433 is highly expressed in the brain tissue [11]. Upregulation of miR-433 inhibits cell migration and proliferation of human umbilical vein vascular endothelial cells and neurons by targeting the Hypoxia-Inducible Factor-1α (HIF-1α) [14]. Further study is warranted to evaluate the functions of these miRNAs, and their role in acute ischemic stroke pathophysiology.

Our study has limitations due to being conducted in a single-center, using a relatively small number of patients. An independent replication cohort is essential to validate the novel findings in this study.

Conclusion
This study demonstrated the potential of serum miR-125a-5p, miR-125b-5p, and miR-433-5p as biomarkers for diagnosing posterior circulation infarction among patients presenting with acute vertigo.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12883-020-01946-3.

Additional file 1: Supplementary Method. Supplementary Result. Table 2. Univariate and multivariate logistic regression for diagnosis of stroke. Table 3. Spearman’s correlation coefficients for the association between miRNA levels and NIHSS. Table 4. Spearman’s correlation coefficients for the association between miRNA levels and infarction volume. Table 5. Spearman’s correlation coefficients for the association between miRNA level and onset to blood collection time. Table 6. P values of the AUROC comparison between individual miRNA levels and a combination of miRNAs. Figure 1. Venn diagram of potential miRNA candidates. Figure 2. AUROC of potential miRNA candidates.

Abbreviations
miRNA: micro-Ribonucleic Acid; RT-qPCR: Quantitative reverse transcription polymerase chain reaction; AUROC: Area under the receiver operating characteristic curve; HINTS: Head impulse test, nystagmus, and test of skew; CT: Computed tomography; MRI: Magnetic resonance imaging; BPPV: Benign paroxysmal positional vertigo; NIHSS: National Institute of Health Stroke Scale; SD: Standard deviation; IQR: Interquartile range

Acknowledgments
The authors are grateful for the technical assistance of Vorthon Sawaswong, and Dr. Kritsada Khongnomman. We also thank all members of the emergency department, otolaryngology department, and stroke unit at the King Chulalongkorn Memorial Hospital for assistance with patient recruitment and sample collection.

Authors’ contributions
NK, SP, TP, and NCS developed the main conceptual idea and research design. NK, PN, AK, NJ, and PV performed experiment and data acquisition. NK, PN, and SJK analyzed the data. NK wrote the manuscript. SP, AC, and SJK edited manuscript. NCS supervised, critically reviewed, and edited the manuscript. All authors approved the final version of the manuscript.

Funding
The study was funded by the 90th Anniversary of Chulalongkorn University Fund (grant number GGUGR1125604019D) (Ratchadaphiseksomphot Endowment Fund) and the Ratchadaphiseksomphot Endowment Fund, Faculty of Medicine, Chulalongkorn University (grant number RA-MF-3/63). Dr. Kijpaisaratana was supported by the 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship. The funders had no role in study design, data collection, data analysis, and manuscript preparation.

Availability of data and materials
The datasets are available from the corresponding author upon reasonable request, after clearance by the institutional ethics committee.

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No. 131/60). Written informed consent was obtained from every patient prior to the enrollment.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok 10330, Thailand. 2Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 3Chula Neuroscience Center; King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 4Center of Excellence in Systems Biology, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 5Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 6Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 7Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 8Otoneurology Unit, Otolaryngology Department, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. 9UCL Ear Institute, Faculty of Brain Science, University College London, London, UK. 10Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 11The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 12The Kirby Institute, The University of New South Wales, Sydney, Australia.
References

1. Kattah JC, Talkad AV, Wang DZ, Hsieh Y-H, Newman-Toker DE. HINTS to diagnose stroke in the acute vestibular syndrome: Three-Step Bedside Oculomotor Examination More Sensitive Than Early MRI Diffusion-Weighted Imaging. Stroke. 2009;40:3504–10.

2. Choi JH, Park MG, Choi SY, Park KP, Balk SK, Kim JS, et al. Acute transient vestibular syndrome: prevalence of stroke and efficacy of bedside evaluation. Stroke. 2017;48:556–62.

3. Simmons Z, Biller J, Adams HP Jr, Dunn V, Jacoby CG. Cerebellar infarction: comparison of computed tomography and magnetic resonance imaging. Ann Neurol. 1986;19:291–3.

4. Bartel DP. miRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

5. Vijayan M, Reddy PH. Peripheral biomarkers of stroke: focus on circulatory microRNAs. Biochim Biophys Acta. 2016;1862:1984–93.

6. Etheridge A, Lee J, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011;717:85–90.

7. Mirzaei H, Momenni F, Saadatpour L, Sahebkar A, Goodarzi M, Masoudifar A, et al. MicroRNA: relevance to stroke diagnosis, prognosis, and therapy. J Cell Physiol. 2018;233:856–65.

8. Tiedt S, Prestel M, Malik R, Schieberdecker N, Duering M, Kautzky V, et al. RNA-Seq identifies circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as potential biomarkers for acute ischemic stroke. Circ Res. 2017;121:970–80.

9. von Brevern M, Bertholon P, Brandt T, Fife T, Imai T, Nuti D, et al. Benign paroxysmal positional vertigo: Diagnostic criteria Consensus document of the Committee for the Classification of Vestibular Disorders of the Barany Society. J Vestib Res. 2015;25:105–17.

10. Lopez-Escamiz JA, Carey J, Chung W, Goebel JA, Magnusson M, Mandala M, et al. Diagnostic criteria for Meniere's disease consensus document of the Barany society, the Japan Society for Equilibrium Research, the European academy of otology and Neurotology (EAONO), the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and the Korean balance society. J Vestib Res. 2015;25:1–7.

11. Mei Q, Li X, Meng Y, Wu Z, Guo M, Zhao Y, et al. A facile and specific assay for quantifying miRNA by an optimized RT-qPCR approach. PLoS One. 2012;7:e46890.

12. Wu J, Fan CL, Ma LJ, Liu T, Wang C, Song JX, et al. Distinctive expression signatures of serum microRNAs in ischemic stroke and transient ischemic attack patients. Thromb Haemost. 2017;117:992–1001.

13. Creemers Esther E, Tijen Anke J, Pinto Yigal M, van Rooij E. Circulating MicroRNAs. Circ Res. 2012;110:483–95.

14. Reijerkerk A, Lopez-Ramirez MA, van Hext Hof B, Drijfhout JAR, Kamphuis WW, Kooij G, et al. MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: implications for multiple sclerosis. J Neurosci. 2013;33:6857–63.

15. He X-W, Shi Y-H, Liu Y-S, Li G-F, Zhao R, Hu Y, et al. Increased plasma levels of miR-124-3p, miR-125b-5p and miR-192-5p are associated with outcomes in acute ischemic stroke patients receiving thrombolyis. Atherosclerosis. 2019;289:36–43.

16. He XW, Shi YH, Zhao R, Liu YS, Li GF, Hu Y, et al. Plasma levels of miR-125b-5p and miR-206 in acute ischemic stroke patients after recanalization treatment: a prospective observational study. J Stroke Cerebrovasc Dis. 2019;28:1654–61.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions